Neil Vasan, MD, PhD is a breast oncologist, physician scientist, Assistant Professor of Medicine, and Director of Breast Cancer Translational Research at the NYU Grossman School of Medicine and Perlmutter Cancer Center at NYU Langone Health. His laboratory (vasanlab.org) studies how kinases and other proteins regulate breast cancer signaling, growth, and therapeutic response. Dr. Vasan received his AB/AM from Harvard University and his MD/PhD from Yale University School of Medicine, and he completed clinical training in internal medicine at Massachusetts General Hospital. He completed his fellowship in medical oncology at Memorial Sloan Kettering Cancer Center (MSKCC) where he was a Chief Fellow and the final fellow to train under the late José Baselga, whose mentorship and vision in translational oncology continues to influence his work. As a postdoctoral fellow funded by a Conquer Cancer/BCRF Young Investigator Award, he identified double PIK3CA mutations as an oncogenic alteration which has gone from bench to bedside as a cancer genomic biomarker. Prior to NYU, he held previous faculty positions at MSKCC and Columbia University Irving Medical Center. His research has been published in Science, Nature, Cancer Cell, and Cancer Discovery. His research awards include the 2023 NIH Director’s New Innovator Award (DP2), Susan G. Komen Career Catalyst Research grant, American Association for Cancer Research (AACR) NextGen Star, and American Society for Clinical Investigation (ASCI) Young Physician Scientist Award. Dr. Vasan is the Scientific Advisor for PIK3CA Pathbreakers, a breast cancer patient advocacy group. Additionally, he serves as Acting Chair and a Standing Member of the U.S. Food and Drug Administration Oncologic Drugs Advisory Committee (ODAC).